GO:0030214 hyaluronan catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030214 (hyaluronan catabolic process) describes the biochemical breakdown of hyaluronan, a non-sulfated glycosaminoglycan composed of repeating beta(1,4)-D-glucuronic acid-beta(1,3)-N-acetyl-D-glucosamine disaccharide units.
• Hyaluronan turnover is a tightly regulated process that balances synthesis by hyaluronan synthases (HAS1, HAS2, HAS3) with degradation by hyaluronidases (HYAL1, HYAL2, HYAL3, HYAL4, PH20/SPAM1) and oxidative fragmentation.
• Catabolic products of hyaluronan, particularly low-molecular-weight fragments, act as signaling molecules that influence cell proliferation, migration, inflammation, and angiogenesis.
• Dysregulated hyaluronan catabolism is implicated in cancer progression, chronic inflammation, and tissue remodeling disorders, making it a target for therapeutic intervention.
• CD44 is the principal cell surface receptor for hyaluronan and mediates its internalization and subsequent degradation in lysosomes.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of hyaluronan catabolic pathway genes in health and disease.
Description
Hyaluronan (HA) is a high-molecular-weight glycosaminoglycan ubiquitously present in the extracellular matrix of vertebrate tissues. Its catabolic process, annotated as GO:0030214, encompasses the chemical reactions and pathways that result in the breakdown of this large polysaccharide into smaller fragments and eventually monosaccharides. This process is essential for maintaining tissue homeostasis, as the balance between HA synthesis and degradation determines the molecular weight distribution of HA, which in turn dictates its biological functions. Researchers study hyaluronan catabolism because HA fragments of specific sizes can act as potent signaling molecules, influencing processes such as inflammation, cell migration, and angiogenesis. Moreover, alterations in HA turnover are associated with numerous pathological conditions, including cancer, fibrosis, and inflammatory diseases. Understanding the molecular players and regulatory mechanisms of HA catabolism is therefore critical for developing targeted therapies and for interpreting experimental data in matrix biology.
hyaluronan catabolic process At A Glance
| GO ID | GO:0030214 |
|---|---|
| GO term | hyaluronan catabolic process |
| Ontology | biological_process |
| Synonym | hyaluronan breakdown; hyaluronan catabolism; hyaluronan degradation |
| Major function | Breakdown of hyaluronan into smaller fragments and monosaccharides |
| Key enzymes | Hyaluronidases (HYAL1, HYAL2, HYAL3, HYAL4, PH20/SPAM1) |
| Key receptors | CD44, HARE/STAB2, LYVE1 |
| Subcellular location | Extracellular matrix, cell surface, lysosome |
| Related processes | Glycosaminoglycan catabolic process, extracellular matrix organization |
What Is GO:0030214?
GO:0030214, hyaluronan catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of hyaluronan, the naturally occurring anionic form of hyaluronic acid. Hyaluronan is a non-sulfated glycosaminoglycan composed of repeating disaccharide units of beta(1,4)-D-glucuronic acid and beta(1,3)-N-acetyl-D-glucosamine. This process includes enzymatic cleavage by hyaluronidases, oxidative degradation, and receptor-mediated internalization followed by lysosomal hydrolysis.
Why Is hyaluronan catabolic process Important in Cell Biology?
The hyaluronan catabolic process is crucial for tissue homeostasis because it controls the concentration and molecular weight of HA, which directly affects cell signaling, matrix hydration, and mechanical properties of tissues. Dysregulation of HA degradation contributes to cancer progression, where HA fragments promote tumor cell proliferation and metastasis, and to inflammatory diseases such as arthritis and hepatitis. Furthermore, HA catabolism is involved in developmental processes, wound healing, and aging. Studying this process provides insights into fundamental matrix biology and offers potential therapeutic targets for a range of diseases.
• Regulates extracellular matrix turnover and tissue remodeling.
• Controls the generation of bioactive HA fragments that modulate inflammation and angiogenesis.
• Influences cancer progression by affecting tumor cell proliferation, migration, and invasion.
• Plays a role in developmental processes and tissue morphogenesis.
• Impacts wound healing and fibrosis through HA fragment-mediated signaling.
• Affects joint health; HA degradation products are implicated in osteoarthritis.
• Modulates immune cell activation and trafficking via CD44 and TLR interactions.
• Contributes to aging phenotypes; enhanced HA synthesis in naked mole-rats improves healthspan in mice.
• Serves as a target for drug delivery systems exploiting CD44-mediated internalization.
• Provides biomarkers for cancer and inflammatory conditions.
What Happens During hyaluronan catabolic process?
Initiation by Hyaluronidases
In simple terms: Enzymes called hyaluronidases cut long hyaluronan chains into smaller pieces.
The catabolic process begins with the cleavage of high-molecular-weight hyaluronan by hyaluronidases, a family of enzymes that hydrolyze the beta-N-acetyl-D-glucosamine linkages. HYAL2, a glycosylphosphatidylinositol-anchored enzyme, is thought to initiate degradation at the cell surface, generating intermediate-sized HA fragments. These fragments can then be further degraded by HYAL1, an acid-active hyaluronidase, within lysosomes. The activity of these enzymes is tightly regulated and varies among tissues.
Receptor-Mediated Internalization
In simple terms: Cells take in hyaluronan fragments through receptors like CD44.
CD44, the principal cell surface receptor for hyaluronan, binds HA and mediates its internalization via endocytosis. This process is critical for the clearance of HA from the extracellular matrix and for the delivery of HA fragments to lysosomes for complete degradation. Other receptors such as HARE (STAB2) and LYVE1 also participate in HA uptake in specific cell types, including sinusoidal endothelial cells and lymphatic endothelial cells.
Lysosomal Degradation
In simple terms: Inside lysosomes, enzymes break down hyaluronan fragments into simple sugars.
After internalization, HA fragments are transported to lysosomes, where acid-active hyaluronidases (e.g., HYAL1) and exoglycosidases sequentially degrade them into monosaccharides, primarily glucuronic acid and N-acetylglucosamine. These monosaccharides can be recycled or further metabolized. Defects in lysosomal hyaluronidase activity lead to HA accumulation and are associated with lysosomal storage disorders.
Oxidative Fragmentation
In simple terms: Reactive oxygen species can also chop up hyaluronan without enzymes.
In addition to enzymatic cleavage, hyaluronan can be fragmented by reactive oxygen species (ROS) during oxidative stress, a process that occurs in inflammation and tissue injury. This non-enzymatic degradation generates a heterogeneous mixture of HA fragments that can perpetuate inflammatory responses. The relative contribution of oxidative versus enzymatic degradation depends on the physiological context.
Fate of Degradation Products
In simple terms: The small hyaluronan pieces can send signals or be further broken down.
The oligosaccharides and monosaccharides generated from HA catabolism can act as signaling molecules by engaging receptors such as TLR2 and TLR4, thereby modulating immune responses. Alternatively, they can be taken up by cells and catabolized to CO2 and water or used for biosynthesis. The balance between these fates influences tissue homeostasis and disease progression.
Key Genes Involved in GO:0030214 hyaluronan catabolic process
The following genes and proteins are central to the hyaluronan catabolic process, encompassing enzymes, receptors, and regulatory factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HYAL1 | Lysosomal hyaluronidase that degrades HA fragments | Mutations cause mucopolysaccharidosis IX; target in cancer therapy |
| HYAL2 | Cell surface hyaluronidase that initiates HA cleavage | Key for HA turnover; implicated in tumor suppression |
| HYAL3 | Hyaluronidase with unclear physiological function | Potential role in HA metabolism; understudied |
| HYAL4 | Hyaluronidase with chondroitinase activity | May contribute to HA degradation in specific tissues |
| SPAM1 (PH20) | Sperm adhesion molecule with hyaluronidase activity | Involved in fertilization and HA degradation |
| CD44 | Principal HA receptor mediating internalization | Critical for HA uptake and signaling; cancer stem cell marker |
| STAB2 (HARE) | Scavenger receptor for HA clearance | Mediates HA turnover in liver endothelial cells |
| LYVE1 | Lymphatic vessel endothelial HA receptor | Involved in HA trafficking and lymphangiogenesis |
| HAS1 | Hyaluronan synthase producing HA | Balances catabolism; affects HA molecular weight |
| HAS2 | Hyaluronan synthase producing high-MW HA | Overexpression improves healthspan in mice |
| HAS3 | Hyaluronan synthase producing lower-MW HA | Regulates HA size and function |
| TLR2 | Toll-like receptor recognizing HA fragments | Mediates inflammatory signaling by HA oligosaccharides |
| TLR4 | Toll-like receptor recognizing HA fragments | Involved in innate immune response to HA degradation products |
| NFKB1 | Transcription factor downstream of HA signaling | Regulates inflammatory gene expression |
| CD44v | CD44 variant isoforms | Associated with cancer progression and HA binding |
| HMMR (RHAMM) | Alternative HA receptor | Mediates HA signaling in cell motility |
| ITIH | Inter-alpha-trypsin inhibitor heavy chains | Can covalently modify HA and affect its catabolism |
| CEMIP (KIAA1199) | Hyaluronan-binding protein involved in HA depolymerization | Plays a role in HA catabolism in cancer |
How Is hyaluronan catabolic process Regulated?
The hyaluronan catabolic process is regulated at multiple levels. Transcriptional regulation of hyaluronidases and receptors (e.g., CD44) modulates catabolic capacity. Post-translational modifications, such as glycosylation of HYAL enzymes, affect their activity and stability. The acidic pH of lysosomes is essential for HYAL1 activity, linking catabolism to lysosomal function. Inflammatory cytokines (e.g., TNF-alpha, IL-1beta) can upregulate hyaluronidases and CD44, enhancing HA turnover during inflammation. Additionally, oxidative stress can promote non-enzymatic HA fragmentation, bypassing enzymatic regulation. The interplay between synthesis (HAS enzymes) and degradation determines the final HA molecular weight and biological outcome.
hyaluronan catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HYAL1 | Mucopolysaccharidosis IX; cancer progression | HYAL1 knockout mice; cancer cell lines with HYAL1 overexpression |
| CD44 | Cancer stem cell maintenance; inflammation | CD44 knockout mice; CD44 point mutations to disrupt HA binding |
| HAS2 | Aging; cancer; inflammation | HAS2 transgenic mice; knock-in of human HAS2 |
| TLR4 | Inflammatory signaling by HA fragments | TLR4 knockout mice; point mutations in TLR4 ligand-binding domain |
| CEMIP | Cancer metastasis; HA depolymerization | CEMIP knockout cell lines; overexpression models |
Hyaluronan Catabolism in Cancer
In many cancers, elevated hyaluronan catabolism correlates with poor prognosis. HA fragments generated by hyaluronidases promote tumor cell proliferation, migration, and angiogenesis through CD44 and TLR-mediated signaling. For example, HYAL1 overexpression is associated with invasive bladder and prostate cancers. CD44, the major HA receptor, is a marker of cancer stem cells and facilitates HA internalization, contributing to chemoresistance. Targeting HA catabolism, such as with hyaluronidase inhibitors or CD44-blocking agents, is an active area of therapeutic research.
Inflammatory and Autoimmune Conditions
Dysregulated HA catabolism contributes to chronic inflammation. Low-molecular-weight HA fragments act as danger signals by activating TLR2 and TLR4 on immune cells, leading to cytokine release and tissue damage. In rheumatoid arthritis, increased hyaluronidase activity and HA fragmentation exacerbate joint inflammation. Similarly, in hepatitis and inflammatory bowel disease, HA fragments perpetuate inflammatory cycles. Modulating HA degradation may offer therapeutic benefits in these conditions.
Lysosomal Storage Disorders
Deficiencies in lysosomal hyaluronidases, particularly HYAL1, cause mucopolysaccharidosis IX (MPS IX), a rare lysosomal storage disorder characterized by HA accumulation in tissues and joints. Patients present with periarticular soft tissue masses and short stature. This disorder highlights the critical role of enzymatic HA catabolism in normal physiology.
Aging and Tissue Homeostasis
Alterations in HA metabolism are linked to aging. In naked mole-rats, enhanced expression of Has2, which produces high-molecular-weight HA, improves healthspan in mice, suggesting that HA catabolism balance affects aging. Conversely, accumulation of HA fragments due to increased catabolism may promote age-related inflammation and tissue dysfunction. Understanding HA turnover in aging could lead to interventions that extend healthspan.
From hyaluronan catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does HYAL1 loss cause HA accumulation? | HYAL1 knockout mice or cell lines |
| How does CD44-mediated internalization affect HA catabolism? | CD44 knockout and point-mutation (HA-binding deficient) models |
| What is the effect of HYAL2 overexpression on tumor growth? | HYAL2 overexpression cell lines and xenografts |
| Can tagged HYAL1 reveal its subcellular localization? | Knock-in of fluorescently tagged HYAL1 |
| Does a specific HYAL1 polymorphism affect enzyme activity? | Point mutation knock-in of the variant |
| What genes regulate HA catabolism in a genome-wide screen? | CRISPR library screening in HA-accumulating reporter cells |
How to Study the hyaluronan catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Hyaluronidase activity assay | Enzymatic cleavage of HA | Validating HYAL1/HYAL2 function after CRISPR editing |
| Size-exclusion chromatography | Molecular weight distribution of HA | Assessing HA degradation in cell culture or tissue extracts |
| Fluorescent HA uptake assay | Receptor-mediated internalization | Studying CD44 function and trafficking |
| RNA-seq | Transcriptional changes | Identifying genes regulated by HA catabolism |
| Proteomics | Protein expression and modifications | Discovering novel HA-binding proteins |
| CRISPR library screening | Genes affecting HA catabolism | Unbiased discovery of pathway regulators |
| Immunofluorescence | Subcellular localization of HA and enzymes | Visualizing HA degradation in situ |
| Mass spectrometry | HA fragment composition | Characterizing degradation products |
Biochemical Assays for Hyaluronidase Activity
Hyaluronidase activity can be measured using substrate-based assays, such as the Morgan-Elson method or fluorogenic HA derivatives. These assays quantify the release of reducing sugars or fluorescent fragments, providing kinetic parameters for enzymes like HYAL1 and HYAL2. They are essential for validating the functional impact of CRISPR edits.
Molecular Weight Analysis of Hyaluronan
The size distribution of HA before and after catabolism can be determined by gel electrophoresis, size-exclusion chromatography, or mass spectrometry. These methods reveal the extent of degradation and the generation of bioactive fragments. They are critical for linking catabolic activity to biological outcomes.
Imaging HA Uptake and Degradation
Fluorescently labeled HA (e.g., HA-FITC) can be used to visualize receptor-mediated internalization and lysosomal trafficking in live cells. Co-localization with lysosomal markers (e.g., LAMP1) confirms delivery to degradative compartments. This approach is valuable for studying CD44 and other receptors.
Genomic and Proteomic Profiling
RNA-seq and proteomics can identify genes and proteins differentially expressed upon modulation of HA catabolism. CRISPR screening combined with HA-binding reporters enables unbiased discovery of novel regulators. These high-throughput methods accelerate target identification.
How CRISPR Can Be Used to Study GO:0030214 hyaluronan catabolic process
Knockout
CRISPR knockout of hyaluronan catabolic genes (e.g., HYAL1, HYAL2, CD44) enables researchers to assess loss-of-function phenotypes, such as HA accumulation, altered cell migration, or changes in signaling. Knockout cell lines and mice are valuable for validating the role of specific enzymes in HA turnover.
Point Mutation
Introducing precise point mutations in catalytic residues of hyaluronidases (e.g., HYAL1) or in the HA-binding domain of CD44 allows dissection of enzymatic activity versus receptor function. Such models help distinguish between structural and signaling roles of HA catabolism components.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA epitope) of HYAL enzymes or CD44 facilitates real-time imaging and proteomic analysis of HA catabolism. Knock-in of disease-associated variants (e.g., HYAL1 mutations) can model lysosomal storage disorders.
Overexpression
Overexpression of hyaluronidases (e.g., HYAL1, PH20) or HAS enzymes using CRISPR activation or lentiviral vectors can increase or decrease HA catabolism, respectively. These models are useful for studying the effects of HA fragment accumulation on tumor growth and inflammation.
How EDITGENE Supports hyaluronan catabolic process Research
Researchers studying hyaluronan catabolic process-related genes often need to determine whether a candidate gene is causally involved in HA turnover or whether its manipulation alters disease phenotypes. Precise genetic models are essential to establish causality and to dissect molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR services tailored to hyaluronan catabolism research, enabling the creation of knockout, point-mutation, knock-in, and overexpression cell models, as well as high-throughput screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for hyaluronan catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLC9A1 Knockout HEK293 Cell Line | EDJ-KQ1430 | Human | 6548 | Details Get a Quote |
| HYAL1 Knockout HEK293 Cell Line | EDJ-KQ2118 | Human | 3373 | Details Get a Quote |
| HMMR Knockout HEK293 Cell Line | EDJ-KQ3029 | Human | 3161 | Details Get a Quote |
| CEMIP2 Knockout HEK293 Cell Line | EDJ-KQ3068 | Human | 23670 | Details Get a Quote |
| LYVE1 Knockout HEK293 Cell Line | EDJ-KQ3152 | Human | 10894 | Details Get a Quote |
| CD44 Knockout HEK293 Cell Line | EDJ-KQ3375 | Human | 960 | Details Get a Quote |
| GUSB Knockout HEK293 Cell Line | EDJ-KQ4034 | Human | 2990 | Details Get a Quote |
| HEXA Knockout HEK293 Cell Line | EDJ-KQ4857 | Human | 3073 | Details Get a Quote |
| HYAL2 Knockout HEK293 Cell Line | EDJ-KQ5631 | Human | 8692 | Details Get a Quote |
| HYAL4 Knockout HEK293 Cell Line | EDJ-KQ8065 | Human | 23553 | Details Get a Quote |
| STAB2 Knockout HEK293 Cell Line | EDJ-KQ11970 | Human | 55576 | Details Get a Quote |
| CEMIP Knockout HEK293 Cell Line | EDJ-KQ12153 | Human | 57214 | Details Get a Quote |
| HEXB Knockout HEK293 Cell Line | EDJ-KQ13743 | Human | 3074 | Details Get a Quote |
| SPAM1 Knockout HEK293 Cell Line | EDJ-KQ15429 | Human | 6677 | Details Get a Quote |
| FGF2 Knockout HEK293 Cell Line | EDJ-KQ17695 | Human | 2247 | Details Get a Quote |
Displaying Records 1 To 15 Of 71 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About hyaluronan catabolic process
What is GO:0030214?
GO:0030214 is the Gene Ontology term for hyaluronan catabolic process, defined as the chemical reactions and pathways resulting in the breakdown of hyaluronan, a non-sulfated glycosaminoglycan.
What genes are involved in hyaluronan catabolic process?
Key genes include hyaluronidases (HYAL1, HYAL2, HYAL3, HYAL4, PH20/SPAM1), receptors (CD44, STAB2, LYVE1), and regulatory factors such as TLR2/TLR4.
How is hyaluronan degraded in cells?
Hyaluronan is degraded by hyaluronidases at the cell surface and in lysosomes, and can also be fragmented by reactive oxygen species. Receptor-mediated internalization via CD44 delivers HA to lysosomes for complete breakdown.
What diseases are associated with defective hyaluronan catabolism?
Defects in hyaluronan catabolism are linked to mucopolysaccharidosis IX (HYAL1 deficiency), cancer progression, chronic inflammation, and aging-related disorders.
What is the role of CD44 in hyaluronan catabolism?
CD44 is the principal cell surface receptor for hyaluronan; it mediates HA internalization and subsequent lysosomal degradation, and also transduces signals that affect cell behavior.
How can CRISPR be used to study hyaluronan catabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes like HYAL1, CD44, and HAS2 to study their roles in HA turnover and disease.
What are the products of hyaluronan catabolism?
Hyaluronan catabolism generates smaller HA fragments (oligosaccharides) and ultimately monosaccharides (glucuronic acid and N-acetylglucosamine), which can have signaling functions or be further metabolized.
Is hyaluronan catabolism involved in cancer?
Yes, increased hyaluronan catabolism and HA fragments promote tumor cell proliferation, migration, and angiogenesis, often via CD44 and TLR signaling.
What methods are used to study hyaluronan catabolism?
Common methods include hyaluronidase activity assays, size-exclusion chromatography, fluorescent HA uptake assays, RNA-seq, proteomics, and CRISPR screening.
How does oxidative stress affect hyaluronan catabolism?
Reactive oxygen species can non-enzymatically fragment hyaluronan, generating pro-inflammatory fragments that contribute to tissue damage.
Conclusion
The hyaluronan catabolic process (GO:0030214) is a fundamental biological pathway that controls the turnover of a major extracellular matrix component. Its dysregulation is implicated in cancer, inflammation, lysosomal storage disorders, and aging. Advances in CRISPR-based gene editing and high-throughput screening are providing new insights into the molecular players and regulatory mechanisms of HA catabolism. Continued research in this area holds promise for developing targeted therapies that modulate HA turnover for therapeutic benefit.
References
- 1. Zhang Z et al.. 2023. Increased hyaluronan by naked mole-rat Has2 improves healthspan in mice.. Nature 621(7977):196-205 PMID: 37612507
- 2. Laurent TC. 1987. Biochemistry of hyaluronan.. Acta Otolaryngol Suppl 442:7-24 PMID: 3124495
- 3. Nisha R et al.. 2022. Assessment of hyaluronic acid-modified imatinib mesylate cubosomes through CD44 targeted drug delivery in NDEA-induced hepatic carcinoma.. Int J Pharm 622:121848 PMID: 35613653
- 4. Skandalis SS et al.. 2020. Intracellular hyaluronan: Importance for cellular functions.. Semin Cancer Biol 62:20-30 PMID: 31276783
- 6. Vigetti D et al.. 2014. Hyaluronan: biosynthesis and signaling.. Biochim Biophys Acta 1840(8):2452-9 PMID: 24513306
- 7. Simpson MA et al.. 2014. Hyaluronan signaling and turnover. Preface.. Adv Cancer Res 123:xv-xvi PMID: 25081537
- 8. Kremmidiotis G. 1999. CD44.. J Biol Regul Homeost Agents 13(4):234-9 PMID: 10703949
